Podcast: Do PI signatures really signal meaningful oversight?
Tracy Vanderslice, VP of Clinical Operations at Gilead Sciences, who also works with TransCelerate, explains the current issues and what can be done to improve these, while not overburdening sites.

Industry partnership will determine the success of the transition to low-GWP pMDIs
TrialAssure selected as EMA’s official clinical trial anonymisation partner
ASCO26: AI innovations show promise in reducing the oncology RWD burden
Keeping pace with generative AI in pharmaceutical and healthcare organisations